Myovant: Relugolix Phase 3 Study Meets Endpoints In Advanced Prostate Cancer

 

Myovant: Relugolix Phase 3 Study Meets Endpoints In Advanced Prostate Cancer

Lynn Seely, CEO of Myovant Sciences, said: “We are now closer to our goal of bringing a precision oral medicine to the broad spectrum of men with advanced prostate cancer.” Shares of Myovant Sciences …

More Myovant: Relugolix Phase 3 Study Meets Endpoints In Advanced Prostate Cancer Videos

Leave a Reply